THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA

被引：0

作者：

Teschemaker, A. R. ^{[1
]}

Neslusan, C. ^{[1
]}

Sabapathy, S. ^{[2
]}

Yoong, K. ^{[2
]}

Johansen, P. ^{[3
]}

Willis, M. ^{[3
]}

机构：

[1] Janssen Global Serv LLC, Raritan, NJ USA

[2] Janssen Inc, Toronto, ON, Canada

[3] Swedish Inst Hlth Econ, Lund, Sweden

来源：

VALUE IN HEALTH | 2015年 / 18卷 / 03期

关键词：

D O I：

10.1016/j.jval.2015.03.365

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PDB58

引用

页码：A62 / A63

页数：4

共 50 条

[41] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
Lavalle Gonzalez, Fernando J.
Januszewicz, Andrzej
Davidson, Jaime
Qiu, Rose
Tong, Cindy
Meininger, Gary
DIABETES, 2013, 62 : A61 - A61
[42] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
Gilbert, Richard E.
Weir, Matthew R.
Fioretto, Paola
Law, Gordon
Usiskin, Keith
Meininger, Gary
DIABETES, 2014, 63 : A267 - A267
[43] Saxagliptin (SAXA) Reduces A1C and Is Well Tolerated in Patients With Type 2 Diabetes (T2DM) and Albuminuria
Bonora, Enzo
Cook, William
Bryzinski, Brian
Hirshberg, Boaz
Allen, Elsie
DIABETES, 2013, 62 : A669 - A669
[44] Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4
Pilon, Dominic
Durkin, Michael
Manceur, Ameur
Ghelerter, Isabelle
Lafeuille, Marie-Hel
Lefebvre, Patrick
DIABETES, 2020, 69
[45] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
Willis, M.
He, J.
Neslusan, C.
Johansen, P.
Worbes-cerezo, M.
VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
[46] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
Ramirez de Arellano, A.
Brosa, M.
Franch, J.
Mauricio, D.
Alvarez, C.
Sanchez-Zamorano, M.
De Rivas, B.
VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
[47] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
Arinina, E. E.
Rashyd, M.
VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
[48] ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
McEwan, P.
Evans, L. M.
Bergenheim, K.
VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
[49] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN (FORXIGA®) VERSUS A DPP-4 INHIBITOR IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN ENGLAND AND WALES
Charokopou, M.
McEwan, P.
Lister, S.
Callan, L.
Bergenheim, K.
Tolley, K.
Roudaut, M.
VALUE IN HEALTH, 2013, 16 (07) : A440 - A440
[50] Perceptions of Type 2 diabetes mellitus (T2DM) among Chinese patients living in Scotland
Wilson, S. L.
Shepherd, C. K.
Lawton, J.
PSYCHOLOGY & HEALTH, 2008, 23 : 274 - 274

← 1 2 3 4 5 →